GlassScriptPhysician profile
Aarthi Vijaykumar
NPI 1821215856
$1,148.00
in general payments reported to CMS, 2019-2025
18 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2021: $60.71 · 2023: $404 · 2024: $354 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.23 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $276.43 | 2019-2024 | Prolia, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $222.14 | 2019-2024 | Farxiga |
| Fresenius USA Marketing, INC. | $159.55 | 2023-2024 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $78.06 | 2023-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $76.00 | 2023-2025 | Rayaldee |
| Akebia Therapeutics INC | $47.93 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $43.93 | 2021-2023 | Oxlumo |
| Novartis Pharmaceuticals Corporation | $30.85 | 2025 | |
| Vifor Pharma, INC. | $27.78 | 2023 | Veltassa |
| Aurinia Pharma U.S., INC. | $26.15 | 2024 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $25.19 | 2025 | Livtencity |
| Bayer Healthcare Pharmaceuticals INC. | $24.04 | 2024 | |
| Shire North American Group INC | $22.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.99 | 2024 | Jardiance |
| Horizon Therapeutics Plc | $21.54 | 2023 | Krystexxa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.08 | 2025 | Arexvy, Shingrix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.66 | 2024 | |
| Mallinckrodt Hospital Products INC. | $13.30 | 2024 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aarthi Vijaykumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.